A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- Objective Tumor Response Rate at 3, 6, and 12 Months
研究概览
简要总结
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or metastatic thyroid cancer that did not respond to iodine therapy.
详细描述
OBJECTIVES:
Primary
- Determine the all-measurable-disease response rate in patients with iodine-refractory locally advanced or metastatic thyroid cancer treated with gefitinib.
Secondary
- Determine the toxicity of this drug in these patients.
- Determine progression-free and overall survival of patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed thyroid cancer, metastatic or locally advanced, not amenable or refractory to local therapy and/or radioactive iodine, depending on the cell type.
- •Thyroid cancer that is unresponsive or refractory to radioactive iodine. All medullary and anaplastic thyroid carcinomas will be considered unresponsive on the basis of histopathologic diagnosis alone. Well-differentiated thyroid cancers (papillary and follicular) will be considered refractory if either there is no evidence of uptake on radioactive iodine scanning or tumor growth persists in spite of treatment with radioactive iodine.
- •Measurable disease.
- •Patient is at least 18 years of age.
- •Eastern Cooperative Oncology Group performance status of 0-
- •If female and of reproductive potential, a negative β-HCG (human chorionic gonadotropin) and use of effective birth control for the course of the study.
- •Patient is capable of providing signed, informed consent.
排除标准
- •Concurrent chemotherapy, concurrent systemic anticancer treatment, or concurrent radiation therapy. Patients will not be excluded from the study on the basis of prior radiation therapy.
- •Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.
- •Currently pregnant or nursing.
- •Absolute neutrophil count <1.5 × 109/L, platelet count < 75 × 109/L, bilirubin > 1.5 × normal, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × normal.
- •Serum creatinine greater than Common Toxicity Criteria (CTC) grade
- •Concomitant use of phenytoin, carbamazepine, barbiturates, rifampin, St John's Wort.
- •Concomitant use of systemic retinoids, cyclosporine, verapamil, diltiazem, nicardipine, nifedipine, nitrendipine, erythromycin, theophylline, ketoconazole, itraconazole, and antihistamines such as terfenadine and astemizole.
- •Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy.
- •Incomplete healing from previous oncologic or other major surgery.
- •Known severe hypersensitivity to ZD1839 or any of the excipients of this product.
- •As judged by the investigator, any evidence of severe or uncontrolled systemic disease
- •(e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- •Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.
- •Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)
研究组 & 干预措施
Gefitinib 250mg
干预措施: Gefitinib (Drug)
结局指标
主要结局
Objective Tumor Response Rate at 3, 6, and 12 Months
时间窗: 3 Months, 6 Months, 1 Year
Response rate as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Tumor assessment is performed within 4 weeks of initiation of treatment and then every 8 weeks. If a patient has stable disease for four tumor assessments (6 months), then tumor assessment may occur every 4 months. If the patient continues to experience stable disease after 2 years, tumor assessments may occur every 6 months. If the patient continues to experience stable disease after 5 years, tumor assessments may occur once a year. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD
次要结局
- Toxicity(Through study completion, on average 12 months)
- Median Progression-free Survival(From the time of enrollment until disease progression or death, whichever came first)
- Overall Survival(5 years)
研究者
John Ross Clark
Physician
Massachusetts General Hospital